Qing zhao

CEO

Cambrian Neuroscience Ltd.

Short Biography

Dr. Zhao graduated from China Pharmaceutical University. He has been engaged in the research and development of innovative drugs for 20 years. He has led and participated in the preclinical research, clinical research and project management of 5 innovative drugs, 3 improved new drugs and over 10 generic drugs, and has obtained 8 production and clinical approval documents. He has presided over multiple major scientific research projects at the national, provincial and municipal levels, published 15 SCI papers and obtained over 50 invention patents. In 2022, he founded Cambrian Neuroscience Ltd, creating a high-content screening and development technology platform for nervous system drugs (CNS) that replicates brain functions through brain-like neural networks and assists AI in analyzing the effects of drugs. This technical platform has screened out more than ten specific candidate drugs, such as Alzheimer's disease, depression, schizophrenia, ataxia, and drug addiction.

Presentation Topic: Brain-like neural networks (BNNs) + AI enhance CNS drug discovery
Brain-like neural networks, which simulate the biological environment of the brain, are rich in components such as neurons, glial cells, synapses, and receptors, providing as many drug binding targets as possible.
Neural network activities directly characterize the impact of different molecules on brain functions, reflect the material basis of various brain activities, and show sufficient sensitivity and diversity to different types of drugs.
It meets the requirements of high throughput and high content, significantly reduces the usage of animal models, greatly improves efficiency and lowers costs. A revolutionary technology that can quickly identify candidate drugs with potential development value.